Sector Expert: Jeffrey Frelick



Recent Quotes

"We reiterate our Buy rating on QDEL, as increased flu activity will support the new Sofia immunoassay platform launch."

— Jeffrey Frelick, Canaccord Genuity (12/2/12)
more >

"We are certain QDEL can drive $100M of new product revenues by 2014."

— Jeffrey Frelick, Canaccord Genuity (4/25/12)
more >

"We have confidence in QDEL's growth prospects."

— Jeffrey Frelick, Canaccord Genuity (3/25/12)
more >



Due to permission requirements, not all quotes are shown.